Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway

<div>Myr treatment prevented Traf6 ubiquitination <i>in vitro</i>. (a) Myr (20 <i>μ</i>M, preincubation with NRCM for 1 h) treatment prevented PE (50 <i>μ</i>M, 30 min) induced TRAF6 ubiquitination and the phosphorylation of p38 and JNK1/2; (b) Myr treatment inhibited K63-Ub-induced TRAF6 ubiquitination in HEK293 cell; (c) Myr inhibited the interaction between Traf6 and TAK1, and TAK1phosphorylation. All experiments were repeated three times independently.</div>

Oxidative Medicine and Cellular Longevity

fig6

Figure 6

Figure 6: Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway 